508 related articles for article (PubMed ID: 15915007)
1. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
Bousquet J; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():13-9. PubMed ID: 15915008
[TBL] [Abstract][Full Text] [Related]
3. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
Dusser D; Vicaut E; Lefrançois G;
Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
Molimard M; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():28-34. PubMed ID: 15915010
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
Houghton CM; Langley SJ; Singh SD; Holden J; Monici Preti AP; Acerbi D; Poli G; Woodcock A
Br J Clin Pharmacol; 2004 Oct; 58(4):359-66. PubMed ID: 15373928
[TBL] [Abstract][Full Text] [Related]
6. Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients.
Langley SJ; Houghton CM; Singh SD
Respiration; 2005; 72 Suppl 1():35-7. PubMed ID: 15915011
[TBL] [Abstract][Full Text] [Related]
7. Bronchodilation of formoterol administered with budesonide: device and formulation effects.
Miller CJ; Senn S; Mezzanotte WS
Contemp Clin Trials; 2008 Mar; 29(2):114-24. PubMed ID: 17625985
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.
Rennard SI; Tashkin DP; McElhattan J; Goldman M; Ramachandran S; Martin UJ; Silkoff PE
Drugs; 2009; 69(5):549-65. PubMed ID: 19368417
[TBL] [Abstract][Full Text] [Related]
10. Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPD.
Brusasco V; Canonica GW; Dal Negro R; Scano G; Paggiaro P; Fabbri LM; Barisione G; D'Amato G; Varoli G; Baroffio M; Milanese M; Mereu C; Crimi E
J Aerosol Med Pulm Drug Deliv; 2011 Oct; 24(5):235-43. PubMed ID: 21689019
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
Tashkin DP; Rennard SI; Martin P; Ramachandran S; Martin UJ; Silkoff PE; Goldman M
Drugs; 2008; 68(14):1975-2000. PubMed ID: 18778120
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial.
Noonan M; Rosenwasser LJ; Martin P; O'Brien CD; O'Dowd L
Drugs; 2006; 66(17):2235-54. PubMed ID: 17137405
[TBL] [Abstract][Full Text] [Related]
13. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma.
Corren J; Korenblat PE; Miller CJ; O'Brien CD; Mezzanotte WS
Clin Ther; 2007 May; 29(5):823-843. PubMed ID: 17697902
[TBL] [Abstract][Full Text] [Related]
14. Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer.
Dubakiene R; Nargela R; Sakalauskas R; Vahteristo M; Silvasti M; Lähelmä S
Respiration; 2006; 73(4):441-8. PubMed ID: 16432294
[TBL] [Abstract][Full Text] [Related]
15. The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma.
Murphy K; Nelson H; Parasuraman B; Boggs R; Miller C; O'Dowd L
Curr Med Res Opin; 2008 Mar; 24(3):879-94. PubMed ID: 18267051
[TBL] [Abstract][Full Text] [Related]
16. Comparable long-term safety and efficacy of a novel budesonide/formoterol pressurized metered-dose inhaler versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma.
Morice AH; Hochmuth L; Ekelund J; Thorén A; Puterman AS
Pulm Pharmacol Ther; 2008; 21(1):32-9. PubMed ID: 17118686
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of formoterol delivered through the Novolizer, a novel dry powder inhaler (DPI) compared with a standard DPI in patients with moderate to severe asthma.
Otto-Knapp R; Conrad F; Hösch S; Metzenauer P; Maus J; Noga O; Petzold U; Kunkel G
Pulm Pharmacol Ther; 2008; 21(1):47-53. PubMed ID: 17475527
[TBL] [Abstract][Full Text] [Related]
18. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma.
Dahl R; Creemers JP; Van Noord J; Sips A; Della Cioppa G; Thomson M; Andriano K; Kottakis J; Fashola T
Respiration; 2004; 71(2):126-33. PubMed ID: 15031566
[TBL] [Abstract][Full Text] [Related]
19. Bronchoprotection with formoterol via dry powder and metered-dose inhalers in patients with asthma.
Lipworth BJ; Sims EJ; Das SK; Morice AH; O'Connor BJ
Ann Allergy Asthma Immunol; 2005 Sep; 95(3):283-90. PubMed ID: 16200820
[TBL] [Abstract][Full Text] [Related]
20. Lung function and asthma control with beclomethasone and formoterol in a single inhaler.
Huchon G; Magnussen H; Chuchalin A; Dymek L; Gonod FB; Bousquet J
Respir Med; 2009 Jan; 103(1):41-9. PubMed ID: 18977646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
